Brief: Alligator Bioscience Announces Continued Overall Survival Benefit For Mitazalimab
26/02/2025 08:24
Feb 26 (Reuters) - Alligator Bioscience AB ATORX.ST: ALLIGATOR BIOSCIENCE ANNOUNCES CONTINUED ENCOURAGING OVERALL SURVIVAL BENEFIT FOR MITAZALIMAB RESULTS SHOW 24-MONTH SURVIVAL RATE OF 29.4% FOR MITAZALIMAB IN COMBINATION WITH MFOLFIRINOX TOPLINE DATA FROM 450 ΜG/KG COHORT, FURTHER STRENGTHENS RATIONALE FOR 900 ΜG/KG AS PHASE 3 DOSE REMAINS ON TRACK IN ADVANCING MITAZALIMAB TOWARD CONFIRMATORY CLINICAL TRIALS Source text: ID:nMFN1bwWVy Further company coverage: ATORX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln